Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
26 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
120.1 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
36
36 articles ont été cités au moins 36fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
3 930
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
271
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
93
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre National de la Recherche Scientifique · Université de Lille · Centre Hospitalier Universitaire de Lille
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Tropatepine poisoning and management: a series of 458 cases
2026ArticleClinical Toxicology
PREVENIR-IVF: study protocol for a prospective multicentre randomized open comparative trial, which explores the efficacy of a multidisciplinary platform reducing and preventing reprotoxic environmental exposures in subfertile couples on live birth rate after assisted reproduction treatment
2025ArticleTrials
Design of a laser safety system for S3 project
2025Congrès20th International Conference on Accelerator and Large Experimental Physics Control Systems
Anticipation of pharmacotherapeutic problems prior to allo stem cell transplantation in patients with co-morbidities (SFGM-TC)
2025ArticleBulletin du Cancer
Trends in antidote use in France from 2015 to 2021: a nationwide poison centers study
2025ArticleScientific Reports
A preliminary model to tailor osilodrostat in patients with Adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome
2025ArticleEuropean Journal of Endocrinology
Food Confusion Between Edible and Poisonous Plants: A 22-Year Retrospective of the Southeastern France Poison Control Center
2024ArticleToxins
Method for the detection and quantification of viral contamination during the preparation of gene therapy drugs in a hospital pharmacy.
2024ArticleOccupational and Environmental Medicine
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL NORD - CHU38
BD DE LA CHANTOURNE, 38700 LA TRONCHE
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Nature medicine · 2023
AbstractCannabis use disorder (CUD) is widespread, and there is no pharmacotherapy to facilitate its treatment. AEF0117, the first of a new pharmacological class, is a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1-SSi). AEF0117 selectively inhibits a subset of intracellular effects resulting from Δ9-tetrahydrocannabinol (THC) binding without modifying behavior per se. In mice and non-human primates, AEF0117 decreased cannabinoid self-administration and THC-related behavioral impairment without producing significant adverse effects. In single-ascending-dose (0.2 mg, 0.6 mg, 2 mg and 6 mg; n = 40) and multiple-ascending-dose (0.6 mg, 2 mg and 6 mg; n = 24) phase 1 trials, healthy volunteers were randomized to ascending-dose cohorts (n = 8 per cohort; 6:2 AEF0117 to placebo randomization). In both studies, AEF0117 was safe and well tolerated (primary outcome measurements). In a double-blind, placebo-controlled, crossover phase 2a trial, volunteers with CUD were randomized to two ascending-dose cohorts (0.06 mg, n = 14; 1 mg, n = 15). AEF0117 significantly reduced cannabis’ positive subjective effects (primary outcome measurement, assessed by visual analog scales) by 19% (0.06 mg) and 38% (1 mg) compared to placebo (P < 0.04). AEF0117 (1 mg) also reduced cannabis self-administration (P < 0.05). In volunteers with CUD, AEF0117 was well tolerated and did not precipitate cannabis withdrawal. These data suggest that AEF0117 is a safe and potentially efficacious treatment for CUD.ClinicalTrials.gov identifiers: NCT03325595, NCT03443895 and NCT03717272.
Irish journal of medical science · 2023
Abstract Objective To investigate the frequency and characteristics of adverse drug reactions (ADRs) that occurred on the gerontopsychiatric ward of Hannover Medical School over a 6-year period. Design Retrospective monocentric cohort study. Results Six hundred thirty-four patient cases (mean age 76.6 ± 7.1 years; 67.2% female) were analysed. In total, 92 ADRs in 56 patient cases were registered in the study population. The overall ADR prevalence, the ADR prevalence upon hospital admission, and the ADR prevalence during hospitalisation were 8.8%, 6.3%, and 4.9%, respectively. The most frequent ADRs were extrapyramidal symptoms, alterations in blood pressure or heart rate, and electrolyte disturbances. Of note, two cases of asystole and one case of obstructive airway symptoms related to general anaesthesia in the context of electroconvulsive therapy (ECT) were detected. The presence of coronary heart disease was associated with an increased risk of ADR occurrence (odds ratio (OR) 2.92, 95% confidence interval (CI) 1.37–6.22), while the presence of dementia was associated with a decreased risk of ADR development (OR 0.45, 95% CI 0.23–0.89). Conclusions Type and prevalence of ADRs in the present study were largely in accordance with previous reports. By contrast, we did not observe a relationship between advanced age or female sex and ADR occurrence. We detected a risk signal for cardiopulmonary ADRs related to general anaesthesia in the context of ECT that warrants further investigation. Elderly psychiatric patients should be carefully screened for cardiopulmonary comorbidities before initiation of ECT.
Molecular psychiatry · 2024
AbstractAddictions often develop in a social context, although the influence of social factors did not receive much attention in the neuroscience of addiction. Recent animal studies suggest that peer presence can reduce cocaine intake, an influence potentially mediated, among others, by the subthalamic nucleus (STN). However, there is to date no neurobiological study investigating this mediation in humans. This study investigated the impact of social context and drug cues on brain correlates of inhibitory control in individuals with and without cocaine use disorder (CUD) using functional Magnetic Resonance Imaging (fMRI). Seventeen CUD participants and 17 healthy controls (HC) performed a novel fMRI “Social” Stop-Signal Task (SSST) in the presence or absence of an observer while being exposed to cocaine-related (vs. neutral) cues eliciting craving in drug users. The results showed that CUD participants, while slower at stopping with neutral cues, recovered control level stopping abilities with cocaine cues, while HC did not show any difference. During inhibition (Stop Correct vs Stop Incorrect), activity in the right STN, right inferior frontal gyrus (IFG), and bilateral orbitofrontal cortex (OFC) varied according to the type of cue. Notably, the presence of an observer reversed this effect in most areas for CUD participants. These findings highlight the impact of social context and drug cues on inhibitory control in CUD and the mediation of these effects by the right STN and bilateral OFC, emphasizing the importance of considering the social context in addiction research. They also comfort the STN as a potential addiction treatment target.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Wilderness & environmental medicine · 2025 · Journal Article
Schmitt C, Maillot A, Glaizal M, Simon N, et al.
European journal of endocrinology · 2025 · Journal Article
Piazzola C, Castinetti F, von Fabeck K, Simon N
European journal of hospital pharmacy : science and practice · 2025 · Comparative Study
Moreau F, Décaudin B, Tod M, Odou P, et al.
European journal of hospital pharmacy : science and practice · 2025 · Journal Article
Roche M, Rousseleau D, Danel C, Henry H, et al.
Frontiers in pharmacology · 2025 · Journal Article
Simon N, von Fabeck K
Occupational and environmental medicine · 2025 · Journal Article
Deramoudt L, Pinturaud M, Bouquet P, Goffard A, et al.
Molecular psychiatry · 2024 · Journal Article
Terenzi D, Simon N, Gachomba MJM, de Peretti JL, et al.
Melanoma research · 2024 · Journal Article
Leroy M, Desmedt E, Deramoudt L, Vasseur M, et al.
Journal of clinical medicine · 2024 · Journal Article
Gendelman O, Simon N, Ben-Shabat N, Patt YS, et al.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2024 · Journal Article
Caron G, Vasseur M, Courtin J, Masse M, et al.
Pharmaceuticals (Basel, Switzerland) · 2023 · Journal Article
Cuvelier E, Khazri H, Lecluse C, Hennart B, et al.
Pharmaceutics · 2023 · Journal Article
Roche M, Danel C, Simon N, Kouach M, et al.
Trials · 2025 · Journal Article
Sunyach C, Courbiere B, Simon N, Delva F, et al.
Journal of safety research · 2025 · Journal Article
Cardozo B, Hartley S, Simon N, Alvarez JC
Frontiers in public health · 2023 · Randomized Controlled Trial
Hartley S, Simon N, Cardozo B, Larabi IA, et al.
Clinical toxicology (Philadelphia, Pa.) · 2026 · Journal Article
Glaizal M, Petit M, Schmitt C, Simon N
Frontiers in toxicology · 2026 · Journal Article
von Fabeck K, Glaizal M, Schmitt C, Torrents R, et al.
Bulletin du cancer · 2025 · English Abstract
Farrugia C, Lhostette A, Brasseur M, Biot T, et al.
Bulletin du cancer · 2025 · English Abstract
Renard C, Corbel A, Paillard C, Pochon C, et al.
Irish journal of medical science · 2023 · Journal Article
Heck J, Noltemeyer N, Schulze Westhoff M, Deest-Gaubatz S, et al.
Journal of gastrointestinal cancer · 2023 · Journal Article
Bridoux M, Le Deley MC, Bertrand N, Simon N, et al.
Irish journal of medical science · 2023 · Journal Article
Heck J, Noltemeyer N, Schulze Westhoff M, Deest-Gaubatz S, et al.
Annals of the rheumatic diseases · 2025 · Journal Article
Simon N, Rudjito R, Moll L, Sandor K, et al.
European journal of gastroenterology & hepatology · 2023 · Journal Article
Forster K, Klein F, Simon N, Chhatwal P, et al.
Journal of safety research · 2025 · Journal Article
Cardozo B, Hartley S, Simon N, Alvarez JC
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2025 · Consensus Statement
Pelosi L, Arányi Z, Coraci D, Grimm A, et al.
European journal of clinical pharmacology · 2025 · Journal Article
von Fabeck K, Alvarez JC, Abe E, Simon N
Additional file 3 of Epidemiology and infection control of carbapenem resistant Acinetobacter baumannii and Klebsiella pneumoniae at a German university hospital: a retrospective study of 5 years (2015–2019)
Additional file 3. Pulsed-field gel electrophoresis of the carbapenem resistant Klebsiella pneumoniae cluster in hematology and oncology (original gel).
sj-rar-2-jop-10.1177_02698811221104063 – Supplemental material for Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial
Supplemental material, sj-rar-2-jop-10.1177_02698811221104063 for Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlle
Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial
Background:Sodium oxybate (SMO) has been shown to be effective in the maintenance of abstinence (MoA) in alcohol-dependent patients in a series of small randomized controlled trials (RCTs). These results needed to be con
Knowledge and practices about safe handling regarding the risk of exposure to antineoplastic drugs for caregivers in compounding units and in operating rooms performing HIPEC/PIPAC
IntroductionEver since the late 1970s, occupational exposure associated with the handling of antineoplastic drugs (ADs) in the healthcare environment has been highlighted and demonstrated. Contamination was detected in b
Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study
Abstract Background Aripiprazole is a second-generation antipsychotic, efficacious in patients with schizophrenia during acute episodes. Due to its pharmacological profile, aripiprazole may be of interest in patients wit
CCDC 2404573: Experimental Crystal Structure Determination
Related Article: Simon Nicolas Deger, Anna Mauri, Yang Cui, Sebastian Josef Weishäupl, Ali Deniz Özdemir, Hamad Syed, Aleksandr Ovsianikov, Wolfgang Wenzel, Alexander Pöthig, Jürgen Hauer, Mariana Kozlowska, Roland Augus
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Nature medicine · 2023 · Clinical Trial, Phase I
Haney M, Vallée M, Fabre S, Collins Reed S, et al.